Bio-Rad Labs (BIO) Tops Q1 EPS by $1.54
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bio-Rad Reports First-Quarter 2022 Financial Results
April 28, 2022 4:15 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2022.
First-quarter 2022 net sales were $700.1 million, a decrease of 3.7 percent compared to $726.8 million reported for the first quarter of 2021. On a currency-neutral basis, quarterly sales decreased 0.8 percent compared to the same period in 2021. COVID-related revenue was approximately $45 million in the first quarter of 2022 versus $94 million in the year ago period. Excluding COVID-related sales, revenue increased 6.5% on a currency neutral basis.
First-quarter gross margin was 57.6 percent... More
